Company Description

We are a clinical-stage biotechnology company focused on developing next-generation therapies. Our mission is to develop and deliver safe, effective, and affordable tissue engineering and cell therapy products that address severe conditions with limited treatment options. By leveraging our deep expertise and advancements in tissue engineering and cell therapy, we are developing BonoFill, a personalized, autologous tissue-engineered live-human bone graft, and MesenCure, an enhanced allogeneic cell therapy for inflammation and tissue damage, both of which, we believe, may address significant unmet clinical and market needs. Cell and cell-based therapies, in which therapeutic cells are combined with other modalities, such as scaffolds for tissue engineering, are categorized based on the cells’ origin. Autologous (or self-derived) treatments utilize the patient’s own cells, whereas allogeneic treatments employ cells from external healthy human donors. While autologous cell therapies, especially those harnessing the patient’s immune cells, are predominantly utilized in cancer treatment (immunotherapy), autologous, non-immune cell therapies, mostly involving mesenchymal stomal cells (MSC) and induced pluripotent stem cells, are under extensive investigation for their potential to repair damaged tissue such as bone, cartilage, heart muscle, and more. Within this field of autologous, non-immune cell therapies, our primary focus is on bone regeneration, with the potential to expand in the future to broader applications of MSC-based tissue engineering. Allogeneic cell therapies, particularly those involving MSCs, are being explored for treating various diseases characterized by excessive immune system activity. This is also an area of focus for us. Our research and development efforts within this cell and cell-based therapy space have yielded our two leading product candidates: . BonoFill is a personalized, tissue-engineered, potentially injectable live-human bone graft derived from the patient cells for bone tissue regeneration, which exemplifies the application of autologous cells. BonoFill is designed to address the limitations of existing bone regeneration and reconstruction therapies. This innovative cell-based product candidate combines cells on a three-dimensional (3D) biocompatible and bioactive mineral scaffold cultivated using our proprietary bioreactor growth system. The result is a live bone graft grown ex vivo (outside the human body), which is intended to be tailored to each patient’s unique biological, physical, and clinical needs. The manufacturing process of BonoFill takes approximately two weeks from receiving the patient cell sample. By leveraging the natural compatibility of autologous cells with the patient’s body, BonoFill aims to optimize treatment outcomes, minimize immune reactions, and eliminate the risk of graft failure; and . MesenCure, an enhanced investigational allogeneic cell therapy designed for treating inflammation and tissue damage, is initially seeking indication as an adjunct therapy to standard of care for treating respiratory distress, including Acute Respiratory Distress Syndrome (ARDS), a life-threatening condition caused by the lungs’ inability to adequately oxygenate the body. The active pharmaceutical ingredient in MesenCure is an innovative composition of allogeneic cells derived from healthy donor adipose tissue MSCs through a proprietary process designed to enhance the MSCs’ therapeutic potential. Currently in development to be administered in up to three doses, these cells are designed to target the lungs, presumably leveraging multiple pleiotropic mechanisms to counteract inflammation and foster lung tissue regeneration, with the potential to address the multifaceted pathology of acute lung injury (ALI) and subsequent respiratory distress. --- We were incorporated in the State of Israel on October 4, 1981, as a private company limited by shares under the name Pointout (Israel) Ltd. On January 15, 1989, we changed our name to Pointout Projects Ltd. On March 22, 1993, we changed our name again to Oceana Advanced Industries Ltd. On August 20, 1993, we became a public company in Israel. On May 20, 2012, our name was changed to Bonus Bio Group Ltd. and on October 3, 2013, our name was changed to our current name, Bonus Biogroup Ltd. Our principal executive offices are located at Matam Advanced Technology Park, Building 20, Haifa 3190501, Israel. Our telephone number in Israel is +972-73-206-7100. Our website address is www.bonus-bio.com. Our agent for service of process in the United States is Puglisi & Associates, whose address is 850 Library Avenue, Suite 204, Newark, Delaware, and whose telephone number is (302) 738-6680.